

Oral HIV Pre-Exposure Prophylaxis (PrEP)

The next time your patients need a prescription filled for PrEP, we hope you will refer to this information and consider cost-effective and clinically appropriate PrEP options. Your patients may be eligible for a zero-dollar copay; see criteria below.

PrEP is indicated for HIV-negative individuals at risk of HIV exposure through sex or injection drug use. Oral PrEP is up to 99% effective at preventing HIV acquisition from sex and at least 74% effective from injection drug use*. For your patients who are new to PrEP, consider addressing their potential barriers to adherence with their medication regimen prior to beginning treatment.

FDA-Approved Oral Treatment Options for PrEP		
Cost per claim**: \$ = \$1 – \$500; \$\$ = \$501 – \$1,000; \$\$\$ = \$1,001 – \$1,500; \$\$\$\$ = \$1,501 – \$2,000; \$\$\$\$\$ = \$2,001 – \$2,500		
	Descovy® <i>tenofovir alafenamide (TAF)/emtricitabine (FTC)</i>	Truvada® <i>tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)</i>
Administration	<ul style="list-style-type: none"> Daily oral use. 	<ul style="list-style-type: none"> Daily oral use. PrEP 2-1-1 (intermittent use).
Population studied	<ul style="list-style-type: none"> Cisgender men who have sex with men. Transgender women. <p>NOT approved for individuals at risk from receptive vaginal sex.</p>	<ul style="list-style-type: none"> Cisgender men who have sex with men. Transgender women and men. Cisgender women. Individuals using injectable drugs.
Adverse events	<ul style="list-style-type: none"> Higher risk of metabolic changes in weight and lipids. 	<ul style="list-style-type: none"> Higher risk of renal impairment and bone mineral density loss.
Cost*	\$\$\$\$\$	\$ (generic cost; available as of October 2020)
Zero-dollar copay criteria	<ul style="list-style-type: none"> Therapy is being prescribed for PrEP. The patient is at high risk for HIV infection according to the prescriber. The patient is not at risk for HIV-1 infection from receptive vaginal sex. The patient has a contraindication to or is unable to take, generic emtricitabine/tenofovir disoproxil fumarate (TDF). 	<ul style="list-style-type: none"> Therapy is being prescribed for PrEP. The patient is at high risk for HIV infection according to the prescriber.

**Average overall EmblemHealth/ConnectiCare pricing per prescription as of Q1 2024. Medication coverage may vary by patient and line of business.

Please call our clinical pharmacist **718-938-2174** if you need additional information.

*Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 Update: a clinical practice guideline. [cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf](https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf). Published December 2021.